Genome&Company Adjusts Conversion Price to ₩5,240 from ₩6,420
Genome&Company adjusted its conversion price from ₩6,420 to ₩5,240, effective Oct 13, 2026, due to a decline in market price. The number of shares issuable on conversion rose from 4,205,607 shares to 5,152,671 shares, an increase of 22.5% by our calculation.
Key facts
| Price before adjustment | ₩6,420 |
|---|---|
| Price after adjustment | ₩5,240 |
| Shares before adjustment | 4,205,607 shares |
| Shares after adjustment | 5,152,671 shares |
| Reason | Conversion price adjustment due to decline in market price |
| Effective date | Oct 13, 2026 |
| Increase in shares issuable (calculated) | 22.5% |
Comparison
| Revenue 2025 | ₩24.6bn |
|---|---|
| Revenue 2024 | ₩27.7bn |
| Revenue 2023 | ₩14.3bn |
Context
In the 12 months before this filing, the company issued CB/BW/EB totaling ₩27.0bn. Potential new shares over that period were 5,713,012 shares, or 10.9% of shares, not netting one upward conversion price adjustment.
Key metrics
Potential dilution
| CB/BW/EB issued, last 12 months | ₩27.0bn |
|---|---|
| Rights offering new shares, last 12 months | 1,507,405 shares |
| Potential new shares, last 12 months | 6,660,076 shares (1 upward conversion price adjustment not netted) |
| Potential new shares, % of shares | 12.7% (1 upward conversion price adjustment not netted) |
| Conversion price adjustments, last 12 months | 2 |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗